delveinsight-discount
DelveInsight Blog
Trending:
Eli Lilly’s COVID-19 Antibody trial;...
Jun 02, 2020
Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV...
Introducing a new brand identity, and a ne...
Jan 27, 2020
Today we’re unveiling a new identity and launching a new logo. For any company, to get a new logo designed…
Gold Nanoparticles May Soon Treat Prostate...
Dec 10, 2018
Gold nanoparticles may soon turn out to be a Prostate cancer treatment option. Apparently, there are certain risks as...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epid...
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history ...
Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis...
Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 ...
Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment
Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-we...
A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment
Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landsc...
NexoBrid and its Awaiting US Approval
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
RECENT ARTICLES
-Agonist.png "Toll-like Receptors Agonist")
